Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PTPRN2 antisense RNA 1 (PTPRN2-AS1) is a long non-coding RNA that is transcribed from the antisense strand of the PTPRN2 locus. Classified as an ncRNA, it does not encode a protein and is not currently considered a direct therapeutic target. While many antisense lncRNAs are known to regulate their corresponding sense transcripts or participate in epigenetic regulatory pathways, there is currently little functional or mechanistic information specifically available for PTPRN2-AS1. Its biological roles, disease associations, and implications for therapy remain to be characterized. Its parent sense gene, PTPRN2, is an autoantigen implicated in diabetes, but these roles do not extend directly to the antisense RNA based on current evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PTPRN2 antisense RNA 1 (PTPRN2-AS1).